A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer
C. H. Barrios
No relevant relationships to disclose
R. Bell
Consultant or Advisory Role - Amgen
D. Finkelstein
No relevant relationships to disclose
H. Iwata
No relevant relationships to disclose
M. Martin
Consultant or Advisory Role - Amgen
A. H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. D. Dansey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. E. Coleman
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis
Research Funding - Novartis
Expert Testimony - Novartis